April 3, 2025 - 22:18
Boston Scientific has successfully finalized its acquisition of Bolt Medical, a strategic move aimed at enhancing its portfolio in the medical technology sector. This acquisition comes on the heels of the FDA granting clearance for Bolt Medical’s innovative Intravascular Lithotripsy (IVL) technology, which is designed to treat calcified coronary artery disease.
The IVL system utilizes sonic pressure waves to break down calcium deposits in arteries, facilitating easier stenting procedures. This breakthrough technology is expected to significantly improve patient outcomes and expand treatment options for those suffering from complex cardiovascular conditions.
With the acquisition now complete, Boston Scientific is optimistic about the future. The company plans to officially launch its new IVL system in the first half of 2026, marking a significant advancement in cardiovascular care. This development is anticipated to strengthen Boston Scientific's position in the competitive medical device market, providing healthcare professionals with innovative solutions to enhance patient care.
